MedTrace Logo

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

NCT03798535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1156

Last updated 2025-07-16

No results posted yet for this study

Summary

This is a non-interventional/observational cohort of unresectable Stage III NSCLC patients treated with durvalumab.

The study will be carried out as a retrospective review of established medical records of unresectable Stage III NSCLC patients treated with durvalumab.

Conditions

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2024-07-16
Completion
2024-07-16

Countries

  • Australia
  • Belgium
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03798535 on ClinicalTrials.gov